

09 - References

References

Prescribing in children and adolescents CHAPTER 5 likely to outweigh these risks in moderate to severe depression. Nonetheless, it bears repeating that the risk of suicide should be very carefully monitored.^{3,4,6,31} ■ ■Activation and manic switch Activation adverse effects of antidepressant - medication - including increased activity, restlessness and agitation - occur more commonly in children than in adolescents or adults. These effects, including mild symptoms, may occur in about 10% of children with depression taking SSRIs.^{54,55} They are usually a transient response to starting medication or increasing dose and should be differentiated from manic switch. Conversion to mania is rarer but is observed more often in young people taking antidepressants than in adults.^{56,57} However, there is no clear evidence that this switch is caused by antidepressants.

References

1. Avenevoli S, et al. Major depression in the national comorbidity survey-adolescent supplement: prevalence, correlates, and treatment. *J Am Acad Child Adolesc Psychiatry* 2015; 54:37-44.e32.
2. Rice F, et al. Adolescent and adult differences in major depression symptom profiles. *J Affect Disord* 2019; 243:175-181.
3. Birmaher B, et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. *J Am Acad Child Adolesc Psychiatry* 2007; 46:-1503-1526.
4. National Institute for Health and Care Excellence (NICE). Depression in children and young people: identification and management. NICE Guideline [NG134]. 2019 (last checked December 2023). www.nice.org.uk/guidance/ng134.
5. March J, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS) randomized controlled trial. *JAMA* 2004; 292:807-820.
6. Goodyer IM, et al. Practitioner Review: Therapeutics of unipolar major depressions in adolescents. *J Child Psychol Psychiatry* 2019; 60:232-243.
7. Locher C, et al. Efficacy and safety of selective serotonin reuptake inhibitors, serotonin--norepinephrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents: a systematic review and meta-analysis. *JAMA Psychiatry* 2017; 74:1011-1020.
8. Teng T, et al. Effect of antidepressants on functioning and quality of life outcomes in children and adolescents with major depressive disorder: a systematic review and meta-analysis. *Transl Psychiatry* 2022; 12:183.

9. Vitiello B, et al. Pharmacological treatment of children and adolescents with depression. *Expert Opin Pharmacother* 2016; 17:2273–2279.
10. Walkup JT. Antidepressant efficacy for depression in children and adolescents: industry- and NIMH-funded studies. *Am J Psychiatry* 2017; 174:430–437.
11. Hetrick SE, et al. New generation antidepressants for depression in children and adolescents: a network meta-analysis. *Cochrane Database Syst Rev* 2021; 5:CD013674.
12. Treatment for Adolescents With Depression Study (TADS) Team. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. *Arch Gen Psychiatry* 2007; 64:1132–1143.
13. Cox GR, et al. Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents. *Cochrane Database Syst Rev* 2014; 11:CD008324.
14. Dubicka B, et al. Combined treatment with cognitive-behavioural therapy in adolescent depression: meta-analysis. *Br J Psychiatry* 2010; 197:433–440.
15. Goodyer I, et al. Selective serotonin reuptake inhibitors (SSRIs) and routine specialist care with and without cognitive behaviour therapy in adolescents with major depression: randomised controlled trial. *BMJ* 2007; 335:142.
16. Zhou X, et al. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. *Lancet Psychiatry* 2020; 7:581–601.
17. Poznanski EO, et al. Children's Depression Rating Scale, Revised (CDRS-R). Los Angeles: Western Psychological Services; 1996.
18. Mayes TL, et al. Psychometric properties of the Children's Depression Rating Scale--Revised in adolescents. *J Child Adolesc Psychopharmacol* 2010; 20:513–516.
19. Angold A, et al. Development of a short questionnaire for use in epidemiological studies of depression in children and adolescents. *Int J Methods Psychiatr Res* 1995; 5:237–249.
20. Chorpita BF, et al. Assessment of symptoms of DSM-IV anxiety and depression in children: a revised child anxiety and depression scale. *Behav Res Ther* 2000; 38:835–855.
21. Shaffer D, et al. A children's global assessment scale (CGAS). *Arch Gen Psychiatry* 1983; 40:1228–1231.
22. Hetrick SE, et al. Newer generation antidepressants for depressive disorders in children and adolescents. *Cochrane Database Syst Rev* 2012; 11:CD004851.
23. Cipriani A, et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. *Lancet* 2016; 388:881–890.
24. Brent D, et al. Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA Randomized Controlled Trial. *JAMA* 2008; 299:901–913.
25. Wilens TE, et al. Fluoxetine pharmacokinetics in pediatric patients. *J Clin Psychopharmacol* 2002; 22:568–575.

572 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 5 26. Aurobindo Pharma – Milpharm Ltd. Summary of product characteristics. Fluoxetine 20mg capsules. 2020 (last checked December 2023); <https://www.medicines.org.uk/emc/product/11909/smpc#gref>. 27. Findling RL, et al. The relevance of pharmacokinetic studies in designing efficacy trials in juvenile major depression. *J Child Adolesc Psychopharmacol* 2006; 16:131–145. 28. Rao Y, et al. Efficacy and

tolerability of antidepressant drugs in treatment of depression in children and adolescents: a network meta-analysis. *Zhejiang Da Xue Xue Bao Yi Xue Ban* 2022; 51:480–490. 29. Arango C, et al. Safety and efficacy of agomelatine in children and adolescents with major depressive disorder receiving psychosocial counselling: a double-blind, randomised, controlled, phase 3 trial in nine countries. *Lancet Psychiatry* 2022; 9:113–124. 30. Findling RL, et al. Vortioxetine for major depressive disorder in adolescents: 12-week randomized, placebo-controlled, fluoxetine--referenced, fixed-dose study. *J Am Acad Child Adolesc Psychiatry* 2022; 61:1106–1118.e1102. 31. Dwyer JB, et al. Annual research review: defining and treating pediatric treatment-resistant depression. *J Child Psychol Psychiatry* 2020; 61:312–332. 32. Asarnow JR, et al. Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: predictors and moderators of treatment response. *J Am Acad Child Adolesc Psychiatry* 2009; 48:330–339. 33. Curry J, et al. Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS). *J Am Acad Child Adolesc Psychiatry* 2006; 45:1427–1439. 34. Haapasalo--Pesu KM, et al. Mirtazapine in the treatment of adolescents with major depression: an open-label, multicenter pilot study. *J Child Adolesc Psychopharmacol* 2004; 14:175–184. 35. Emslie GJ, et al. Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes. *Am J Psychiatry* 2010; 167:782–791. 36. Dwyer JB, et al. Efficacy of intravenous ketamine in adolescent treatment-resistant depression: a randomized midazolam-controlled trial. *Am J Psychiatry* 2021; 178:352–362. 37. Di Vincenzo JD, et al. The effectiveness, safety and tolerability of ketamine for depression in adolescents and older adults: a systematic review. *J Psychiatr Res* 2021; 137:232–241. 38. Zhou Y, et al. Effect of repeated intravenous esketamine on adolescents with major depressive disorder and suicidal ideation: a randomized active-placebo-controlled trial. *J Am Acad Child Adolesc Psychiatry* 2024; 63:507–518. 39. Sigrist C, et al. Transcranial magnetic stimulation in the treatment of adolescent depression: a systematic review and meta-analysis of aggregated and individual-patient data from uncontrolled studies. *Eur Child Adolesc Psychiatry* 2022; 31:1501–1525. 40. Cai H, et al. Suicidal ideation and electroconvulsive therapy: outcomes in adolescents with major depressive disorder. *J ECT* 2023; 39:166–172. 41. Zimmermann KS, et al. Esketamine as a treatment for paediatric depression: questions of safety and efficacy. *Lancet Psychiatry* 2020; 7:827–829. 42. Ayvaci ER, et al. Special populations: treatment-resistant depression in children and adolescents. *Psychiatr Clin North Am* 2023; 46:359–370. 43. Varigonda AL, et al. Systematic review and meta-analysis: early treatment responses of selective serotonin reuptake inhibitors in pediatric major depressive disorder. *J Am Acad Child Adolesc Psychiatry* 2015; 54:557–564. 44. Jakubovski E, et al. Systematic review and meta-analysis: dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder. *Am J Psychiatry* 2016; 173:174–183. 45. Heiligenstein JH, et al. Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot study. *J Child Adolesc Psychopharmacol* 2006; 16:207–217. 46. Emslie GJ, et al. Fluoxetine treatment for prevention of relapse of depression in children and adolescents: a double-blind, placebo-controlled study. *J Am Acad Child Adolesc Psychiatry* 2004; 43:1397–1405. 47. Emslie GJ, et al. Fluoxetine versus placebo in preventing relapse of major depression in children and adolescents. *Am J Psychiatry* 2008; 165:459–467. 48. Li K, et al. Risk of suicidal behaviors and antidepressant exposure among children and adolescents: a meta-analysis of observational studies. *Front Psychiatry* 2022; 13:880496. 49. Sharma T, et al. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. *BMJ* 2016; 352:i65. 50. Bridge JA, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. *JAMA* 2007; 297:1683–1696. 51. Plöderl M, et al. Re: "A multicenter double-blind, placebo--

controlled trial of escitalopram in children and adolescents with generalized anxiety disorder” by Strawn et al. – Concerning harm-benefit ratio in a recent trial about escitalopram for generalized anxiety disorder. *J Child Adolesc Psychopharmacol* 2023; 33:295–296. 52. Gibbons RD, et al. Early evidence on the effects of regulators’ suicidality warnings on SSRI prescriptions and suicide in children and adolescents. *Am J Psychiatry* 2007; 164:1356–1363. 53. Libby AM, et al. Decline in treatment of pediatric depression after FDA advisory on risk of suicidality with SSRIs. *Am J Psychiatry* 2007; 164:884–891. 54. Offidani E, et al. Excessive mood elevation and behavioral activation with antidepressant treatment of juvenile depressive and anxiety disorders: a systematic review. *Psychother Psychosom* 2013; 82:132–141. 55. Safer DJ, et al. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. *J Child Adolesc Psychopharmacol* 2006; 16:159–169. 56. Baldessarini RJ, et al. Antidepressant-associated mood-switching and transition from unipolar major depression to bipolar disorder: a review. *J Affect Disord* 2013; 148:129–135. 57. Virtanen S, et al. Antidepressant use and risk of manic episodes in children and adolescents with unipolar depression. *JAMA Psychiatry* 2024; 81:-25–33.

Revision #1

Created 2026-01-04 20:16:32 UTC by Omar Ayman

Updated 2026-01-04 20:16:32 UTC by Omar Ayman